Remove Aortic valve Remove Stenosis Remove TAVR
article thumbnail

Surgical management of native aortic valve leaflet avulsion during TAVR

Journal of Cardiothoracic Surgery

Transcatheter aortic valve replacement (TAVR) has increased in utilization since its approval for management of aortic stenosis patients across all risk strata. We report a rare case of aortic valve leaflet av.

article thumbnail

Alternative access in transcatheter aortic valve replacement—an updated focused review

Frontiers in Cardiovascular Medicine

Aortic Stenosis (AS) is a common condition with an estimated pooled prevalence of all AS in the elderly population at around 12.4%, with that of severe AS estimated to be around 3.4%. In the past, surgical aortic valve replacement was the primary treatment option for severe AS for decades.

article thumbnail

Medtronic Announces FDA Approval of Newest-generation Evolut TAVR System for Treatment of Symptomatic Severe Aortic Stenosis

DAIC

milla1cf Thu, 03/28/2024 - 07:30 March 28, 2024 — Medtronic plc, a global leader in healthcare technology, announced that the United States Food and Drug Administration ( FDA ) has approved the Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis.

TAVR 111
article thumbnail

Sarcopenia and aortic valve disease

Heart BMJ

Valvular heart disease, including calcific or degenerative aortic stenosis (AS), is increasingly prevalent among the older adult population. Over the last few decades, treatment of severe AS has been revolutionised following the development of transcatheter aortic valve replacement (TAVR).

article thumbnail

Almost 50% of Patients Under 60 Years Choose TAVR Over Surgical Aortic Valve Replacement with Worse Outcomes

DAIC

Getty Images milla1cf Mon, 01/29/2024 - 14:24 January 29, 2024 — Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under age 65 with severe aortic stenosis , many hospitals are still opting for a nonsurgical approach in patients under 60—possibly with poorer survival rates.

article thumbnail

Valvular and perivalvular thrombus after TAVR: Risks and Outcomes

Cardiology Update

Transcatheter aortic valve replacement (TAVR) is the standard treatment for severe aortic stenosis, but post-TAVR leaflet thrombus, identified by hypoattenuated leaflet thickening (HALT), poses potential risks like cerebral thromboembolic events. had thrombus at any aortic valve complex.

TAVR 122
article thumbnail

Transcatheter Aortic Valve Replacement Versus Surgical Aortic Valve Replacement for Treating Elderly Patients With Severe Aortic Stenosis and Small Aortic Annuli

American College of Cardiology

The goal of the VIVA trial was to evaluate transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement (SAVR) among patients with severe aortic stenosis and a small aortic annulus.